reason report
bottom line recent host annual next-gen
sequenc tour visit set divers lab
also met manag team assess
broader adopt novaseq year largest
instrument upgrad cycl histori despit current
op valuat price-to-earnings consensu rapid uptak
novaseq seen convers continu suggest
box upgrad cycl novaseq consum pull-through remain
robust across custom base believ pull-through
rise among high-volum lab academ core
rais revenu estim pt
move
room concern sequenc demand remain broad
deep across divers lab custom base met number
custom rang lead high-volum lab
drive develop pediatr neonat intens
whole genom wg assay op high-volum
hereditari reproduct assay doubl volum y/i
academ lab alreadi spend consum
annual among lab found novaseq pend novaseq
purchas number hiseq steadili declin usag
get unplug elast demand lower sequenc cost
drive demand novaseq still howev demand assay
color chemistri like keep number hiseq aliv
manag remain confid upbeat
outlook multi-year novaseq replac cycl met
cfo ad omead ostadan evp product
oper jacqui ross investor relat manag
remain confid multi-year novaseq replac cycl
continu play expect consum
growth increasingli becom measur success
manag also point despit appear
signific drop sequenc cost hiseq
 novaseq flowcel actual weight averag cost
sequenc drop far moder posit
expect catalyz opportun increas reimburs
non-invas pre-nat test nipt work payer drive
adopt oncolog via companion diagnost loxo
compani inform leerink partner llc research
pleas refer page import disclosur price chart analyst certif
manag highlight volum growth declin
cog continu gain market share also met
ceo sean georg eric olivar clinic oper assay
develop plan almost doubl volum test
vs deliv long-term goal reach gross
margin alreadi drove cog lower y/i
gm believ signific room reduc scale
addit help use leverag novaseq reduc
cost novaseq fleet hiseq estim
spend annual number repres
cog stack like go higher accord
room concern elast demand continu drive adopt
novaseq consum pull-through across divers lab custom base
recent host annual next-gen sequenc tour visit set divers
next-gen sequenc lab high-volum test academ core also met
manag team assess broader adopt novaseq
year largest instrument upgrad cycl histori despit current
valuat price-to-earnings consensu rapid uptak novaseq seen
convers continu suggest box upgrad cycl novaseq consum pull-
remain solid across custom base believ pull-through
rise among high-volum lab academ core rais revenu
estim
see room concern sequenc demand remain broad deep across
divers lab custom base beyond manag met number
custom rang
lead high-volum lab drive develop pediatr neonat
intens care whole genom wg assay novaseq anoth one
arriv lab util flowcel predominantli given faster
turnaround time requir pediatr wg make therapi manag decis
almost doubl hereditari reproduct test volum
test path gener gross margin higher
novaseq addit fleet hiseq continu use support
exist test acquisit nvta spend sequenc annual
revenu set go higher given expect demand
academ core lab director expect obtain novaseq current
spend sequenc consum singl cell consum
see sampl demand rise see univers research lab fill
capac sequenc price drop academ institut enjoy discount
list price entir univers system benefit
discount one highest encount far due dilig
continu drive elast demand use novaseq even broadli deliv
sequenc cost half hiseq cost faster turnaround time
introduct novaseq custom gain lower sequenc cost improv
 near messag day clear sequenc
becom cheaper lab abl drive signific volum sampl
experi come tabl cost sequenc drop believ elast
demand continu play marketplac sampl deeper sequenc
continu becom attract sequenc cost per gb even year launch
novaseq see novaseq must-hav lab drive lower cog
compet market
develop wg assay manag pediatr patient
visit larg west coast pediatr hospit highlight util genom sequenc
practic patient everi day birth babi born one
genet diseas genom sequenc could better guid treatment potenti
enhanc clinic outcom west coast hospit focu sequenc
fifteen percent patient sequenc lead diagnosi
case chang treatment regimen thirty-thre percent sequenc patient
receiv diagnosi sequenc patient patient actual
receiv treatment chang basi wg assay
panel exom replic type genet inform medicin lab
gene panel leav lot open-end question panel exom one
requir know specif gene screen rare case rare undiagnos
disord answer question unbias fashion hospit conduct rct
random control trial assess util genom versu exom wg
lab novaseq novaseq purchas pend hiseq
retir wg lab current employ flowcel given faster
turnaround time requir lab sequenc expens year
complet genom bioinformat analysi hour day much faster
anoth major barrier grow market unlock market penetr
payer view genom sequenc given earli stage wg test none
commerci payer current reimburs genom sequenc reimburs within
hospit set philanthrop support hospit wg project continu
grow team expect show alreadi grow cost analysi data payer order drive
coverag decis center broke cost get sequenc per
genom cost attribut sequenc come bioinformat
remain labor sampl prep
manag remain confid sequenc demand remain broad
deep across divers lab custom base
met cfo ad omead ostadan evp product oper
jacqui ross investor relat manag remain confid multi-year novaseq
replac cycl continu play expect consum growth
increasingli becom measur success manag also point despit
appear signific drop sequenc cost hiseq
novaseq flowcel actual weight averag cost sequenc drop far
moder posit
also expect catalyz opportun increas reimburs nipt work
payer drive adopt oncolog via companion diagnost loxo
collabor remain confid demand sampl continu increas
think opportun mainli lie oncolog reimburs transit
whole exom screen whole genom screen futur market driver
immuno-oncolog io compani molecular biolog crispr-focus compani dtc
direct-to-consum market demand compani view success come expans
consum growth expect close tie expans applic
continu doubl volum drive cog lower
also met sean georg ceo eric olivar clinic oper assay
develop identifi drive cog lower drive market share
meet note compani use novaseq drive cog lower test
volum increas compani abl take advantag high-throughput capabl
novaseq current use combin flowcel novaseq
fleet hiseq still like maintain overal util nvta sequenc
 manag note util hiseq typic best suit
overflow capac also note test cog stack
come sequenc cost revenu expect rise
come year
ceo georg believ space consolid one three player
consolid leav still signific room growth price come test
market grown georg note popul cost affect inherit
genet see end demand side equat
academ core bend novaseq elast demand
visit larg univers genom sequenc core spend sequenc
consum toward consum cost toward rapidli grow singl cell
applic genom
lab older instrument feel pressur sequenc price fall lab low
volum struggl keep pace high-throughput sequenc lab academ core
lab visit current sequenc hiseq submit share
instrument grant novaseq base nih fund climat current support
research academ core remain hope receiv novaseq
lab director hope abl get cheaper sequenc maintain rel normal
turnaround time sampl analysi lab switch novaseq biggest
issu would convinc other cost save great enough warrant wait
entir month order aggreg enough sampl allow sequenc cost-
effort remain competit lab plan purchas novaseq expect
use flowcel achiev best sequenc price lab director mention
scientist want run experi limit expens sequenc think
novaseq larg purchas lab becom fruit invest
volum grow highlight elast demand
lab director note initi lag volum sampl upon purchas
instrument idea still volum catch back increas capac
quickli believ novaseq adopt rate continu trend higher near term
trip also saw core academ lab commerci lab activ
look offload hiseq instrument without solicit group essenti
believ instrument becom useless academ core lab manag
compar util hiseq older iphon
medacorp specialist ex-ilmn manag point competit
sustain high consum gross margin locked-down natur novaseq
featur benefit
also spoke medacorp specialist get better look competit landscap
gross margin instrument perform medacorp specialist ex-ilmn manag
point despit lasergen ion torrent oxford nanopor emerg
sequenc compani appear still limit competit howev
specialist point expect clinic market multipl sequenc provid
long-term given uniqu need panel assay
medacorp specialist also appreci locked-down natur novaseq expect
lock-down increas ilmn core sb patent expir alway
possibl new sequenc core ilmn chemistri specialist suggest
requir whole system much beyond chemistri deliv qualiti data deliv
base convers chemistri involv remain convinc enough
room maintain gross margin sequenc consum believ bode well
improv overal margin longer term flowcel instrument margin would also
improv scale
servic
good sold
interest expens incom
add net incom attribut non-control interest
net incom attribut
sg sale
 sale
oper expens sale
sg revenu
 revenu
compani report leerink partner estim
accret redeem prefer
net incom applic common
good sold
sg sale
 sale
oper expens sale
compani report leerink partner estim
rate share outperform price target view
custom compet race reduc sequenc cost
manifest novaseq order believ sequenc market number
sampl depth coverag expand dramat next year novaseq
drive signific reduct sequenc cost hiseq
novaseq flow cell novaseq set path reach research
grade genom longer term price beyond high throughput platform also
continu drive double-digit growth desktop system includ nextseq essenti
key high growth market includ non-invas pre-nat test nipt oncolog
continu domin sequenc market world-wide address market
size life scienc genet test reproduct health oncolog market
share revenu market share sequenc unit believ ilmn market
share accuraci throughput enterpris level servic product factor
continu keep custom bound despit custom consid higher
price still direct strong competit sight somewhat unbound market
believ continu domin next-gen sequenc keep drive sequenc cost
lower lead elast demand sampl deeper sequenc need
share current trade price-to-earnings consensu ep averag
life scienc tool lst group multipl note potenti unbound
market opportun major popul develop develop world
touch sequenc form test next year use
dcf analysi chang beta long-term growth rate wacc
arriv price target revis estim see
revenu growth increas y/i reflect confid manag abil
deliv instrument consum growth addit believ long-term
growth rate conserv estim given sequenc repres somewhat
unbound market opportun opinion still applic continu
explor beyond hereditari somat test oncolog nipt academ
margin profil would face downward pressur given new entrant innov competitor
understand domin market share genom sequenc industri
tmo ion torrent main competit believ major
competit near term product instal expens
competitor given monopoli howev custom balk price major
innov develop futur expect gross oper margin
declin given competit note occupi market share industri
instal base due expens equip instal highlight
import price consum elast product
affect reimburs decis medicar although posit cash
flow critic mass instal base demand genom test product
affect reimburs rate declin reimburs like lead lower demand
product activ turn would affect usag consum product
seen effect reimburs rate chang peer genom test industri
drop would certainli impact revenu believ ilmn growth profil could
significantli slow reimburs rate lower would like contribut
regul fda could major impact revenu well current
sell diagnost product laboratori consid laboratori develop test
ldt fda yet regul ldt due prolifer product
industri fda may revers cours regul ldt addit product requir
fda approv intend use diagnosi diseas
expand product purpos subject greater test complianc
standard increas oper expens believ addit regul
ilmn ldt research-us product would result risk estim
high level capit expenditur involv oper mean disrupt capital-expenditure
spend could lead slower growth level capital-expenditure need launch support new
product import growth slight delay instrument shipment
consum could caus guidanc miss miss guidanc close
one less hiseqx system anticip given small room error
one deal leverag capital-expenditure maintain oper risk
rate share outperform price target high growth
commercial-stag diagnost compani focus build busi around genet test
sizabl grow multibillion dollar market compani broaden oncolog
focus genet test busi includ reproduct health offer via acquisit
start genet combimatrix also launch exom offer
provid deep coverag gene basic coverag gene also
establish partnership biotech biopharma compani rare diseas clinic trial
potenti gener anoth revenu stream long-term nvta assay aggreg gene
indic hereditari cancer syndrom well cardiovascular neurolog pediatr
disord creat comprehens interpret report help clinician appropri
manag patient famili time hope manag genom cours
diseas lifetim facilit databas requir provid patient genet
inform advanc scienc medicin
current trade ev/consensu sale averag
diagnost group multipl consist
fmi believ trade slightli peer group given limit visibl
test product line still reflect natur high growth commercial-stag diagnost
compani focus build busi around genet test sizabl grow multi-
billion dollar market appli discount peer group multipl arriv
sale get price target
reimburs hereditari cancer propos increas
per test rule final reimburs declin nvta ramp would
sever impact given still earli commercial-stag compani look addit
contract order secur futur revenu
gave expect posit gross margin posit cash flow
still plenti uncertainti busi busi develop forecast
expect face challeng earli commercial-stag compani face competit
disadvantag establish competitor
fda regul could impact product number product offer
compani addit increas regul fda requir addit sg expens
satisfi complianc increas cost could also affect abil ramp
compani need anoth round financ exist debt could lead addit
interest expens increas net debt balanc sheet could also lead increas capit
